Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shannon Fryery

Nurse Practitioner, Family Oxford, MS Nurse Practitioner

NPI 1407895725 CMS profile 10865415

2890 S Lamar Blvd, Oxford, MS 38655

Open in the dashboard

General payments

$126,766

715 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Fryery of Oxford, MS is reported in the CMS Open Payments database as having received $126,766 across 715 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,067 158
2024 General $36,796 187
2023 General $20,611 144
2022 General $9,792 118
2021 General $8,501 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Fryery
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Shannon Fryery were reported at $51,067. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Shannon Fryery Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $8,501 $124 $35–$379 $132
2022 $9,792 $141 $44–$430 $149
2023 $20,611 $154 $49–$476 $160
2024 $36,796 $165 $51–$504 $164
2025 $51,067 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $119,711 363 payments
  2. ViiV Healthcare Company $2,397 129 payments
  3. Merck Sharp & Dohme Corporation $934 45 payments
  4. AbbVie, Inc. $866 39 payments
  5. Theratechnologies Inc. $826 38 payments
  6. Insmed, Inc. $674 36 payments
  7. Paratek Pharmaceuticals, Inc. $336 20 payments
  8. Janssen Biotech, Inc. $330 22 payments
  9. Aimmune Therapeutics, Inc. $227 3 payments
  10. La Jolla Pharmaceutical Company $226 13 payments
  11. Other $239 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $86,126 62 payments
  2. Travel and Lodging $21,291 79 payments
  3. Food and Beverage $13,691 562 payments
  4. Consulting Fee $5,480 4 payments
  5. Education $179 8 payments
Products named General payments · program years 2021–2025
  1. Biktarvy $80,262 168 payments
  2. Descovy $6,012 14 payments
  3. DOVATO $1,668 91 payments
  4. Yeztugo $1,088 3 payments
  5. PIFELTRO $757 37 payments
  6. DELSTRIGO $679 33 payments
  7. TROGARZO $653 31 payments
  8. EGRIFTA $637 31 payments
  9. CABENUVA $621 33 payments
  10. Arikayce $555 33 payments
  11. Other $3,645 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

3,250

Median for Nurse Practitioner: 389

Drug cost

$3,719,553

Median for Nurse Practitioner: $21,885

Branded share of claims

44.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 535 $2,133,910
Juluca Dolutegravir/Rilpivirine Brand 127 $448,017
Cabenuva Cabotegravir/Rilpivirine Brand 57 $375,244
Dovato Dolutegravir Sodium/Lamivudine Brand 93 $287,171
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 47 $218,009
Trogarzo Ibalizumab-Uiyk Brand 16 $104,798
Daptomycin Generic 21 $33,750
Descovy Emtricitabine/Tenofov Alafenam Brand 13 $28,167
Januvia Sitagliptin Phosphate Brand 35 $19,808
Imipenem-Cilastatin Sodium Imipenem/Cilastatin Sodium Brand 16 $15,223

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$38,293

Medicare's payments for the services billed

Medicare patients

254

Average age 69

Services billed

591

111 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 48%
Ischemic heart disease 40%
Chronic kidney disease 38%
COPD 32%
Depression 32%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Biktarvy
$25,982 535 —
DOVATO
$264 93 —
NUZYRA
$192 — —
CABENUVA
$186 57 —
MAVYRET
$175 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

715 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record